证券时报e公司讯,复星医药(02196.HK)4月29日晚披露一季报,2020年第一季度公司实现营业收入58.81亿元,同比下滑12.62%;净利润5.77亿元,同比下滑18.97%。
“特别声明:以上作品内容(包括在内的视频、图片或音频)为凤凰网旗下自媒体平台“大风号”用户上传并发布,本平台仅提供信息存储空间服务。
Notice: The content above (including the videos, pictures and audios if any) is uploaded and posted by the user of Dafeng Hao, which is a social media platform and merely provides information storage space services.”